Brand Name: Xhibit Product Name: Xhibit Central Station Model/Catalog Number: 96102 Software V...

FDA Device Recall #Z-2916-2026 - Class II, June 4, 2026

Recall Summary

Recall Number Z-2916-2026
Classification Class II - Moderate risk
Date Initiated June 4, 2026
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Spacelabs Healthcare, Inc.
Location Snoqualmie, WA
Product Type Devices
Quantity 6074

Product Description

Brand Name: Xhibit Product Name: Xhibit Central Station Model/Catalog Number: 96102 Software Version: N/A Product Description: The Spacelabs Healthcare (Spacelabs) Xhibit Central Station, Model 96102. Xhibit offers remote surveillance of patient data for those patients connected to a Spacelabs Healthcare bedside monitors and telemetry systems. The DisplayPort audio/video splitter allows users to extend the audio/video source from the Xhibit to additional external displays or monitors. This extension of audio/video is for viewing only and does not allow interaction with the Xhibit. Component: The DisplayPort audio/video splitter is a 3rd party external accessory to Xhibit.

Reason for Recall

Due to off-the-shelf display port component that has audio/video failures

Distribution Pattern

Worldwide - US Nationwide distribution in the states of AK, AL, AR, AZ, CA, CO, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, VA, WA, WI, WY and the countries of CANADA, FRANCE, ITALY, MALAYSIA, THAILAND.

Lot / Code Information

Model/Catalog Number: 96102 DisplayPort Splitter Part Number: 010-1975-00 UDI-DI codes: 1084152212706 10841522100345 Serial Numbers: Pending

Other Recalls from Spacelabs Healthcare, Inc.

Recall # Classification Product Date
Z-2052-2026 Class II Brand Name: Spacelabs Ultraview SL Command Modu... Mar 26, 2026
Z-1793-2026 Class II Multi-parameter Command Module, Model 91496, op... Feb 27, 2026
Z-0169-2026 Class II Brand Name: Branding is not applied to this pro... Sep 5, 2025
Z-0168-2026 Class II Brand Name: Branding is not applied to this pro... Sep 5, 2025
Z-0167-2026 Class II Brand Name: Branding is not applied to this pro... Sep 5, 2025

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic, removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.